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Abstract
On June 27, 2006, the NIH conducted a workshop to review published data and current field
practices supporting the use of self-obtained vaginal swabs (SOVs) as specimens for diagnosis of
sexually transmitted infections (STIs). The workshop also explored the design of studies that
could support FDA clearance of SOVs for STI testing, particularly for specimens collected in
nonclinical settings including patients’ homes. This report summarizes the workshop findings and
recommendations. Participants concluded that self-obtained vaginal swabs are well accepted by
women of all ages and that SOVs perform as well as or better than other specimen types for
Chlamydia trachomatis and Neisseria gonorrhoeae detection using transcription-mediated
amplification. In addition, workshop participants recommended the validation of SOV testing by
public health practitioners and manufacturers of STI diagnostic tests to expedite incorporation of
SOVs as a diagnostic option in clinical and nonclinical settings for Chlamydia trachomatis and
Neisseria gonorrhoeae testing. Similarly, SOVs should be explored for use in the diagnosis of
other sexually transmitted pathogens.
At the beginning of the 21st century, we face stable or increasing infection rates for
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) in the United States. These are
unacceptable circumstances in view of the serious negative impact of these infections on
reproductive health and their relatively high prevalence in the United States compared with
other industrialized countries.1,2 Clearly, reduction of prevalence and incidence requires
improved intervention approaches, including better screening strategies.
CT and GC infections in the general population are often asymptomatic and consequently
are underdiagnosed.3,4 Targeted screening programs in the United States have resulted in
steady declines in the prevalence of these infections in the 1990s, a trend that unfortunately
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has not been sustained in recent years. Surveillance statistics from the CDC reveal that
reported cases of gonorrhea rose sharply from the mid 1960s through the 1970s, declined
steadily until the mid 1990s and then plateaued.2 Comparable data for CT infections have
been collected only since 1984, and nationwide, case rates appear to have risen steadily
through the most recent annual data summary period in 2005. However, screening for CT
became widespread only after the advent of affordable, reliable detection methods including
nucleic acid amplification tests (NAATs) in the 1990s, and case detection has been
increasing steadily ever since.2 Thus, the apparent increase in CT case detection is likely due
in part to increased case finding. However, in the northwestern states comprising Public
Health Region X, funding for broad-based CT screening among women was initiated in
1988, and data have been collected on the number of tests performed and the percent of CT
tests that were positive. In Region X, CT prevalence rates actually dropped steadily between
1988 and 1995 and then remained steady through 1997 (Fig. 1).5 Data from the regional
Infertility Prevention Programs have provided good CT prevalence data from participating
family planning clinics in the United States since the late 1990s. Infertility Prevention
Programs data show that CT rates in women seen in these settings remained steady
nationwide through 2005.5 Importantly, in Region X, where screening programs have been
in place the longest, the percentage of women tested who have positive tests for CT is now
rising, even after statistical adjustment for increases in test sensitivity (Fig. 1). The reasons
for the lack of continued decline (and even increases) in both CT and GC prevalence are not
entirely clear, but these trends may be consequences of initial screening programs that
targeted only a subset of the population (those who attended the clinics), allowing continued
spread in underserved sectors of the community (those who did not attend the clinics). Thus,
it is logical to conclude that programs for screening all at-risk populations could further
reduce sexually transmitted infection (STI) prevalence.
Possible strategies for reducing STI prevalence include expanding screening to
nontraditional settings such as schools, juvenile detention centers, hospital emergency
departments, and drug rehabilitation clinics. The availability of highly sensitive NAATs
allows the use of specimens other than conventional clinician-obtained endocervical and
urethral specimens, such as urine and vaginal specimens, for detection of CT and GC.
Self-Obtained Vaginal Swab Specimens Perform Well for Detection of CT
and GC Infections
A major breakthrough in screening for CT and GC genital tract infections came with the
recognition that by using highly sensitive NAATs, the organisms could be detected in urine
from infected women.6 Shortly after this discovery, a number of investigators explored the
use of vaginal swabs for detection of CT and GC by ligase chain reaction and transcription-
mediated amplification.7–9 These studies demonstrated that vaginal swabs are as sensitive as
cervical swabs for the detection of CT and GC and more sensitive than urine specimens.
Moreover, a multicenter study underscored the susceptibility of urine specimens to technical
errors resulting from relatively demanding processing requirements, particularly the
centrifugation step, which was unnecessary for vaginal swab specimens.10 In this study, the
sensitivity of cervical swabs was about 90%, whereas sensitivities for vaginal swabs were
greater than 96% for each of the NAAT assays evaluated. In contrast, the combined
sensitivity of urine-based assays in this study was only 81%. Furthermore, self-obtained
vaginal swabs (SOVs) performed as well as clinician-collected vaginal swabs. Some studies
have shown vaginal swab specimens to be more sensitive than endocervical specimens,11,12
although the 2 specimen types showed equivalent performance in most studies.10,13,14
However, for detection of GC in women, not all NAATs exhibit acceptable performance
with specimens other than endocervical swabs. Of particular note, neither urine nor SOVs
showed adequate sensitivity for detection of GC with the Roche Amplicor PCR assay.15 It
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has been clearly demonstrated that the vaginal swab is an acceptable and accurate specimen
type, and use of swab specimens is more sensitive than use of first-catch urine specimens for
detection of CT and GC using transcription-mediated amplification.
Self-Collection of Vaginal Specimens Is Acceptable to Women
Women prefer vaginal swab self-collection over pelvic examination in most settings, and
SOV collection is at least as well accepted as, and often preferred to the collection of first-
catch urines.14 In a longitudinal study of adolescent women, participants were willing to
collect weekly vaginal swabs for STI testing during 12-week periods for up to 6 years.16 In a
recent study in which subjects were recruited via the Internet, over 500 women in the
Baltimore area submitted SOVs for CT and GC testing.17 Women of all ages have proven
willing and capable of SOV collection in a variety of nonclinic settings including homes,16
high schools,18 military bases,19–21 correctional facilities,22,23 university health centers,24
substance abuse treatment facilities,25–27 and geographically remote communities.28–33 Self-
sampling enables STI testing in settings where considerable barriers prevent conventional
specimen collection.
Innovative CT and GC Screening Strategies Are Possible With Self-
Obtained Vaginal Specimens
Currently, the FDA has cleared only 1 CT/GC NAAT (Gen-Probe’s APTIMA Combo2
assay) for use with SOVs, and clearance is limited to self or clinician collection of
specimens in the clinic. This restriction clearly hinders more widespread use of vaginal
swabs and largely negates the advantages offered by self-collection. Therefore, validation
for the use of SOVs in nonclinic settings is urgently needed.
Preliminary studies demonstrated the feasibility of home-based specimen collection for CT
testing. In a Danish study, participants were mailed specimen self collection kits or an
informational packet containing a card that could be mailed in to obtain a kit.34,35 Program
approval was high, and women with access to home specimen collection were 3 to 4 times
more likely to be tested than women who had to visit a physician for testing during usual
care. In the United States, women who were screened using home-collected SOVs received
significantly more tests for gonorrhea and chlamydial infection, compared with women who
received invitations to come into a clinic for testing.36 In a small study in Seattle, patients
with CT or GC infections were contacted posttreatment and invited to participate in a study
for rescreening.37 Among participants given the option to return to the clinic for testing or
collect a specimen at home and mail it to the clinic, 70% opted for self collection, and 60%
of subjects were rescreened. The results of these studies demonstrate the acceptability and
success of CT and/or GC screening using specimens collected at home and mailed into the
laboratory. Screening with home-based specimen collection is likely to be more cost-
effective than clinic-based testing because costs of clinic visits and pelvic examinations
would be eliminated.38
SOVs Expand Our Ability to Study the Epidemiology of STIs in the Field
A fundamental limitation in collection of population-based epidemiologic data is the
requirement that individuals be tested in a clinical setting. Over the last decade, the use of
urine samples has expanded access to field-based settings. However, problems with urine
transport and nucleic acid target instability in urine continue to hamper the study of
nonclinic-based populations. SOVs have the potential to circumvent many of these
problems.
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In a population-based study of adolescent sexual behaviors and risk factors, SOVs were used
for STI diagnostics and experimental detection assays.16,39–42 Prevalence estimates in this
population were established for CT and GC and several other STIs. In addition, this study
followed the natural histories of Trichomonas vaginalis (TV), Mycoplasma genitalium
(MG), and sexually transmitted viral infections in young women. In some cases, a single
SOV was used for detection of DNA from CT, GC, TV, MG, herpes simplex virus (HSV),
and human papillomavirus (HPV). The experience from this study suggests that this method
could be used for population-based screening efforts for numerous sexually transmitted
organisms once appropriate specimen transport and processing conditions are defined.
SOVs Are Optimal Specimens for Detection of T. vaginalis and M.
genitalium Infections
The emphasis on the use of self-obtained specimens for detection of CT and GC reflects
predominant focus in the current literature on studies regarding the use of SOVs for
detection of these infections and the current availability of FDA-cleared tests for diagnosis
of gonorrhea and chlamydial infections. However, the workshop also reviewed the growing
literature on the performance of SOVs for detecting other reproductive tract infections
including TV, MG, HSV, HPV, and bacterial vaginosis.
Compared with tests for CT and GC, development of NAATs for other sexually transmitted
infections has received less attention from the diagnostics industry. However, analyte-
specific reagents for detection of TV are commercially available for use with the Gen-Probe
transcription-mediated amplification (TMA) platform, and a TMA research assay for MG is
in development. In addition, numerous in-house NAATs have been used to detect these
organisms, and published reports suggest that SOVs may be the best specimen for detection
of these 2 increasingly important pathogens.
Unlike CT and GC, which primarily infect the cervix and are shed into the vagina, the
protozoan parasite TV primarily infects the vagina. Thus, vaginal swabs are ideal specimens
for the detection of this widespread, but underdiagnosed sexually transmitted pathogen.
Provider-collected vaginal swabs have long been used to test for trichomoniasis in STD
clinic settings using wet mount microscopy and culture. For detection of TV using culture43
or PCR,12,21,44 test performance is equivalent for SOVs and provider-collected vaginal
swabs. SOVs also perform well with the Gen-Probe TV analyte-specific reagents.45
Furthermore, SOVs have proven superior to urine as specimens for TV PCR.44,46
MG is a newly recognized pathogen associated with reproductive tract infections in both
men and women. In a study of MG infection in women attending a northwestern US STD
clinic, Totten and colleagues compared genital specimen types for MG detection using the
Gen-Probe TMA research assay and in-house PCR assays.47 In this study, vaginal swabs
were superior to cervical swabs and urine specimens in both NAATs for detection of MG.
Thus, in addition to their utility for CT, GC testing, SOVs should facilitate screening
programs for TV and MG.
SOV Used for Detection of HSV, HPV, and Organisms Associated With BV
Self-obtained genital samples including SOVs have played a pivotal role in defining the
natural history of genital herpes and have increasingly been used to evaluate the efficacy of
therapeutics and candidate therapeutic vaccinations.48–51 Because HSV is present on the
mucosa intermittently, one-time cross-sectional population sampling of genital secretions for
the virus will identify only a small proportion of those infected. However, daily self-
obtained swabs of genital mucosa over prolonged intervals in both women and men have
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shown that almost all persons with HSV-2 experience viral reactivation and most have
recurrent genital lesions.52
Unlike the STIs discussed above for which vaginal specimens are appropriate for screening,
SOVs for HPV testing appear less likely to replace cervical specimens for detecting high-
grade cervical lesions and invasive cervical cancer in most clinical settings. As a diagnostic
tool for detecting high-grade cervical lesions and invasive cervical cancer, SOVs have been
reported to be equally or less sensitive than clinician-collected direct cervical sampling, and
less specific.53–63 Nevertheless, SOVs for HPV testing have potential applications for both
clinical practice and research. SOVs may be useful in situations where clinician-performed
sampling is not feasible, and could be effective in increasing screening coverage or
adherence to recommendations for follow-up of equivocal Pap results. As a research tool,
SOVs could allow increased participation in and feasibility of large-scale phase intravenous
vaccine studies designed to investigate HPV transmission dynamics and the population-level
impact of vaccines on HPV prevalence. Initial studies of self-obtained vaginal specimens for
HPV detection are encouraging; several studies reported higher rates of HPV detection in
SOVs than in clinician-collected cervical samples in clinic settings.58,64 In a recent report
published after the workshop, Dunne and colleagues from the CDC describe high HPV
prevalence detected in SOVs collected at home by women in the 2003 to 2004 US National
Health and Nutrition Examination Survey.65 Additional studies are needed to determine the
utility of self-collected vaginal swabs for HPV detection in other nonclinical settings.
In contrast to the genital tract infections caused by individual microbes, bacterial vaginosis
is characterized by the replacement of the normal predominant Lactobacillus vaginal flora
with a mixed flora including Gardnerella vaginalis, anaerobes, and other bacteria. Diagnosis
of BV is generally based either on physical examination or on the assessment of vaginal
bacterial morphotypes by Gram stain.66 SOVs have been used successfully for home-based
collection and clinic-based research studies for BV testing by Gram stain and are acceptable
to women.67–70 A role for SOVs in routine clinical practice and home collection is
promising but currently untested.
What Is the Way Forward?
Abundant evidence supports the use of SOVs for STI testing, most clearly at this time for
detection of CT and GC using transcription-mediated amplification, since the LCR assay is
no longer available. Although no single specimen type will detect all chlamydial or
gonococcal infections, there is ample proof that vaginal swabs perform at least as well as
other specimen types by TMA, and they are clearly superior to the main alternative
noninvasive specimen—first-catch urine. In addition, the simpler processing requirements
for vaginal swabs than for urine make them less susceptible to laboratory error with NAATs
that do not include a target capture step. Women are adept at self-collection, and in settings
where pelvic examinations and traditional specimen collection and testing are not available,
SOVs offer an opportunity to increase screening and thereby hopefully further reduce CT
and GC infections in women. SOVs are the specimen of choice for women in programs for
self-motivated chlamydia and gonorrhea screening. It remains to be seen how widely
acceptable such programs will be for the detection of CT and GC infections among sexually
active, asymptomatic women in the general population. The FDA has cleared the use of kits
for self-motivated, self-collection of specimens for HIV and Hepatitis C testing, and such
kits are available via the Internet and in pharmacies. We anticipate that home-collected and
mailed SOVs will be important in increasing the detection and treatment of chlamydia and
gonorrhea as well as other STIs in women.
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To achieve the maximum immediate benefit, SOVs should be compatible with multiple CT/
GC NAAT platforms. Currently, each test requires a specific transport and storage buffer for
provider-collected cervical or vaginal swabs. In a small preliminary study, the sensitivity of
a commercial PCR test for detection of CT and GC in dry vaginal swabs (transported in
containers with no added liquid) was not statistically different than for swabs that were
placed in specimen transport buffer immediately after collection. 20 We recommend the
development and assessment of a specimen collection kit for mailing dry SOVs to the
laboratory, compatible with all NAAT platforms eventually approved for SOV testing, with
standard reconstitution instructions for optimal performance of this specimen type. In
addition, specimen validation under conditions likely to be encountered during transport by
mail is needed for commercially available NAATs.
From the public health perspective, there are many reasons to encourage more widespread
use of SOVs for the detection of CT, GC and other STI pathogens. STI testing using self-
obtained specimens will not replace clinic-based speculum examination and counseling by
clinicians. However, self-collection programs should enhance participation in targeted
screening programs—for example, for posttreatment detection of recurrent chlamydial
infections in women. Moreover, women should have the opportunity to protect themselves
from the consequences of CT and CG infection through self-motivated specimen self-
collection in their homes if they feel they may be at risk for infection. Validation of SOVs
for this purpose is needed to permit the implementation of such testing as well as the
development of innovative approaches to self-sampling in a wide variety of circumstances.
SOVs may enhance testing for women who refuse an examination, for women in late
pregnancy, or for young women who may not yet need a Papanicolaou smear examination
and may be discouraged from attending the clinic by the prospect of a speculum
examination, yet are at risk of acquiring an STI.15 Early data have shown SOVs and other
self-collected specimens to be effective research tools for TV and MG as well as for
sexually transmitted viruses. SOVs have proven very useful in longitudinal studies of the
natural history of recurrent genital herpes virus infection, and this model could be applied to
studies of the epidemiology and natural history of other STIs as well.
We encourage the STI research community and the public health community to work
together with the diagnostics industry to develop validation protocols for SOVs to obtain the
evidence needed for FDA clearance for their routine use in the diagnosis of CT and GC
infections now, and for other STI pathogens in the near future. The self-obtained vaginal
swab has the potential for use as a “universal” specimen for detection of lower genital tract
infections in women, and will allow the assessment of these infections in an increasingly
wide variety of settings.
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Trends in Chlamydia trachomatis positivity among 15- to 24-year old women tested in
family planning clinics in northwestern states of Public Health Region X, 1988 to 2005.
Data are from the Centers for Disease Control and Prevention.5 Black bars are unadjusted,
and gray bars are adjusted for changes in laboratory test methods and associated increases in
test sensitivity.
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